Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Current Advances in Solid Tumor Mechanisms, Prognoses, or Personalized Treatments
share announcement

Current Advances in Solid Tumor Mechanisms, Prognoses, or Personalized Treatments

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: closed (15 October 2023) | Viewed by 2846

Special Issue Editor

Dr. Jialin Meng

E-Mail Website
Guest Editor
1. Department of Urology, First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
2. Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei 230022, China
Interests: tumor molecular subtyping; tumor immunotherapy; mice model; multiomics analysis; solid tumor prognosis

Special Issue Information

Dear Colleagues,

Solid tumors account for approximately 90 percent of adult cancers. They can appear in a variety of locations across the human body, including in the breast, lung, prostate, colon, melanoma, bladder, and kidney. Solid tumors are heterotypic aggregates of many cell types, including cancer cells, cancer stem cells, connective tissue cells, and immune cells. Therefore, solid tumors are heterogeneous among different patients, which is linked with the diverse activated signaling pathways as well as genetic alterations, resulting in prognoses or medicine resistance.

In recent years, technological breakthroughs in the multiomics era, the wide application of transcriptomics, epigenomics, metabolomics, proteomics, and microbiomics, can deeply dig out the inner characteristics of each type of tumor; even those of each patient. These novel technical approaches, as well as algorithms that integrate different omics data types, can accelerate the identification of molecular patterns associated with solid tumors and guide clinical precision therapy.

We are pleased to invite you to submit papers with results that achieve novel insights into solid tumors, including, but not limited to, their mechanisms, prognoses, or personalized treatments. Articles concerning methods such as multiomics, single-cell, or in vivo experiments are welcome to the current Special Issue.

Dr. Jialin Meng
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • tumor molecular subtyping
  • tumor microenvironment
  • tumor mechanism
  • clinical cohort
  • machine learning
  • single-cell sequence
  • omics data
  • prognosis signature
  • personalized treatment

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 2078 KiB  
Article
Blood Plasma Circulating DNA-Protein Complexes: Involvement in Carcinogenesis and Prospects for Liquid Biopsy of Breast Cancer
by Aleksei Shefer, Oleg Tutanov, Maxim Belenikin, Yuri P. Tsentalovich and Svetlana Tamkovich
J. Pers. Med. 2023, 13(12), 1691; https://doi.org/10.3390/jpm13121691 - 05 Dec 2023
Viewed by 983
Abstract
Circulating DNA (cirDNA) is a promising tool in translational medicine. However, studies of cirDNA have neglected its association with proteins, despite ample evidence that this interaction may affect the fate of DNA in the bloodstream and its molecular functions. The goal of the [...] Read more.
Circulating DNA (cirDNA) is a promising tool in translational medicine. However, studies of cirDNA have neglected its association with proteins, despite ample evidence that this interaction may affect the fate of DNA in the bloodstream and its molecular functions. The goal of the current study is to shed light on the differences between the proteomic cargos of histone-containing nucleoprotein complexes (NPCs) from healthy female (HFs) and breast cancer patients (BCPs), and to reveal the proteins involved in carcinogenesis. NPCs were isolated from the blood samples of HFs and BCPs using affinity chromatography. A total of 177 and 169 proteins were identified in NPCs from HFs and BCPs using MALDI-TOF mass spectrometry. A bioinformatics analysis revealed that catalytically active proteins, as well as proteins that bind nucleic acids and regulate the activity of receptors, are the most represented among the unique proteins of blood NPCs from HFs and BCPs. In addition, the proportion of proteins participating in ion channels and proteins binding proteins increases in the NPCs from BCP blood. However, the involvement in transport and signal transduction was greater in BCP NPCs compared to those from HFs. Gene ontology term (GO) analysis revealed that the NPC protein cargo from HF blood was enriched with proteins involved in the negative regulation of cell proliferation, and in BCP blood, proteins involved in EMT, invasion, and cell migration were observed. The combination of SPG7, ADRB1, SMCO4, PHF1, and PSMG1 NPC proteins differentiates BCPs from HFs with a sensitivity of 100% and a specificity of 80%. The obtained results indirectly indicate that, in tandem with proteins, blood cirDNA is an important part of intercellular communication, playing a regulatory and integrating role in the physiology of the body. Full article
(This article belongs to the Special Issue Current Advances in Solid Tumor Mechanisms, Prognoses, or Personalized Treatments)
►▼ Show Figures

Figure 1

15 pages, 55372 KiB  
Article
Identifying Oxidized Lipid Metabolism-Related LncRNAs as Prognostic Biomarkers of Head and Neck Squamous Cell Carcinoma
by Ziwei Zhang, Byeong Seop Kim, Wenqing Han, Xiaojun Chen, Yingjie Yan, Li Lin and Gang Chai
J. Pers. Med. 2023, 13(3), 488; https://doi.org/10.3390/jpm13030488 - 08 Mar 2023
Viewed by 1097
Abstract
The relationship between oxidized lipid metabolism and the immunological function of cancer is well known. However, the functions and regulatory mechanisms of lncRNAs associated with oxidized lipid metabolism in head and neck squamous cell carcinoma (HNSCC) remain to be fully elucidated. In this [...] Read more.
The relationship between oxidized lipid metabolism and the immunological function of cancer is well known. However, the functions and regulatory mechanisms of lncRNAs associated with oxidized lipid metabolism in head and neck squamous cell carcinoma (HNSCC) remain to be fully elucidated. In this study, we established an oxidized lipid metabolism-related lncRNA prognostic signature to assess the prognosis and immune infiltration of HNSCC patients. The HNSCC transcriptome was obtained from The Cancer Genome Atlas. The choice of the target genes with a relevance score greater than 10 was performed via a correlation analysis by GeneCards. Patients were categorized by risk score and generated with multivariate Cox regression, which was then validated and evaluated using the Kaplan–Meier analysis and time-dependent receiver operating characteristics (ROC). A nomogram was constructed by combining the risk score with the clinical data. We constructed a risk score with 24 oxidized lipid metabolism-related lncRNAs. The areas’ 1-, 2-, and 3-year OS under the ROC curve (AUC) were 0.765, 0.724, and 0.724, respectively. Furthermore, the nomogram clearly distinguished the survival probabilities of patients in high- and low-risk groups, between which substantial variations were revealed by immune infiltration analysis. The results supported the fact that oxidized lipid metabolism-related lncRNAs might predict prognoses and assist with differentiating amid differences in immune infiltration in HNSCC. Full article
(This article belongs to the Special Issue Current Advances in Solid Tumor Mechanisms, Prognoses, or Personalized Treatments)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop